Govindan, US
Madhu Saravana Govindan, Austin, TX US
Patent application number | Description | Published |
---|---|---|
20090125293 | Method and System for Real-Time Prediction of Power Usage for a Change to Another Performance State - A method and system for real-time prediction of power usage for a change to another performance state provides input data for power management decision-making processes or for display to system operators. The unit(s) for which power usage is predicted may be a single processor in a uni-processor system or may extend up to the level of facilities within a complex of processing facilities. The method and system gather real-time data on the power consumption of the unit(s) and create a model, such as a regression model, of power versus performance. A resulting power usage change required by a prospective nominal performance state change is shown as display data, or is transmitted to a power budgeting controller to inform the controller as to potential changes that can enhance system operation, such as managing tradeoffs of power allocated to various sub-units of a processing system. | 05-14-2009 |
Madhu Saravana Sibi Govindan, Austin, TX US
Patent application number | Description | Published |
---|---|---|
20130145180 | METHOD OF POWER CALCULATION FOR PERFORMANCE OPTIMIZATION - A system and method for efficient management of operating modes within an IC for optimal power and performance targets. On a same die, an SOC includes one or more processing units and a input/output (I/O) controller (IOC). The multiple interfaces within the IOC manage packets and messages according multiple different protocols. The IOC maintains an activity level for each one of the multiple interfaces. This activity level may be based at least on a respective number of transactions executed by a corresponding one of the multiple interfaces. The IOC determines a power estimate for itself based on at least the activity levels. In response to detecting a difference between the power estimate and an assigned I/O power limit for the IOC, a power manager adjusts at least respective power limits for the one or more processing units based on at least the difference. | 06-06-2013 |
20140149772 | Using a Linear Prediction to Configure an Idle State of an Entity in a Computing Device - The described embodiments include a computing device with one or more entities (processor cores, processors, etc.). In some embodiments, during operation, a thermal power management unit in the computing device uses a linear prediction to compute a predicted duration of a next idle period for an entity based on the duration of one or more previous idle periods for the entity. Based on the predicted duration of the next idle period, the thermal power management unit configures the entity to operate in a corresponding idle state. | 05-29-2014 |
20140173298 | PERFORMANCE AWARE IDLE POWER MANAGEMENT - Methods, systems, and media are provided for power management. The power management includes, but is not limited to storing at a computer system a history of canceled entries into a low power state that interrupted a transition of the unit from an active mode to the low power state and disallowing transition of the unit into the low power state when a number of canceled entries indicated by the history of canceled entries exceeds a canceled entry threshold. | 06-19-2014 |
20140181413 | METHOD AND SYSTEM FOR SHUTTING DOWN ACTIVE CORE BASED CACHES - A system and method are presented. Some embodiments include a processing unit, at least one memory coupled to the processing unit, and at least one cache coupled to the processing unit and divided into a series of blocks, wherein at least one of the series of cache blocks includes data identified as being in a modified state. The modified state data is flushed by writing the data to the at least one memory based on a write back policy and the aggressiveness of the policy is based on at least one factor including the number of idle cores, the proximity of the last cache flush, the activity of the thread associated with the data, and which cores are idle and if the idle core is associated with the data. | 06-26-2014 |
20150185801 | POWER GATING BASED ON CACHE DIRTINESS - Power gating decisions can be made based on measures of cache dirtiness. Analyzer logic can selectively power gate a component of a processor system based on a cache dirtiness of one or more caches associated with the component. The analyzer logic may power gate the component when the cache dirtiness exceeds a threshold and may maintains the component in an idle state when the cache dirtiness does not exceed the threshold. Idle time prediction logic may be used to predict a duration of an idle time of the component. The analyzer logic may then selectively power gates the component based on the cache dirtiness and the predicted idle time. | 07-02-2015 |
20150198991 | PREDICTING POWER MANAGEMENT STATE DURATIONS ON A PER-PROCESS BASIS - Durations of power management states are predicted on a per-process basis. Some embodiments include storing, in one or more data structures associated with one or more processes, information indicating previous durations of a power management state associated with the process(es). Some embodiments also include predicting a subsequent duration of the power management state for the process(es) using information stored in the data structure(s). | 07-16-2015 |
Madhu Sarvana Sibi Govindan, Austin, TX US
Patent application number | Description | Published |
---|---|---|
20130262780 | Apparatus and Method for Fast Cache Shutdown - An apparatus and method to enable a fast cache shutdown is disclosed. In one embodiment, a cache subsystem includes a cache memory and a cache controller coupled to the cache memory. The cache controller is configured to, upon restoring power to the cache subsystem, inhibit writing of modified data exclusively into the cache memory. | 10-03-2013 |
Mahdu S.s. Govindan, Austin, TX US
Patent application number | Description | Published |
---|---|---|
20140181553 | Idle Phase Prediction For Integrated Circuits - A method and apparatus for idle phase prediction in integrated circuits is disclosed. In one embodiment, an integrated circuit (IC) includes a functional unit configured to cycle between intervals of an active state and an idle state. The IC further includes a prediction unit configured to record a history of idle state durations for a plurality of intervals of the idle state. Based on the history of idle state durations, the prediction unit is configured to generate a prediction of the duration of the next interval of the idle state. The prediction may be used by a power management unit to, among other uses, determine whether to place the functional unit in a low power (e.g., sleep) state. | 06-26-2014 |
20140181556 | Idle Phase Exit Prediction - A method and apparatus for exiting a low power state based on a prior prediction is disclosed. An integrated circuit (IC) includes a functional unit configured to, during operation, cycle between intervals of an active state and intervals of an idle state. The IC also include a power management unit configured to place the functional unit in a low power state responsive to the functional unit entering the idle state. The power management unit is further configured to preemptively cause the functional unit to exit the low power state at a predetermined time after entering the low power. The predetermined time is based on a prediction of idle state duration made prior to entering the low power state. The prediction may be generated by a prediction unit, based on a history of durations of intervals in which the functional unit was in the idle state. | 06-26-2014 |
Manoj Govindan, Gastonia, NC US
Patent application number | Description | Published |
---|---|---|
20100332243 | Goal Insurance - Goal insurance is provided as a purchasable option to users who wish to have a goal tracking system monitor and enforce their goals. The user may define the goal, a reward to be given upon successful completion of the goal and penalties to be applied if the goal is not met. To avoid penalties, the user may purchase goal insurance that may be used or apply under specified circumstances. Such circumstances may include death, illness, unemployment or the like. Goal information and progress may be monitored by the goal tracking system and may further be published to one or more sites. Other users may contribute to the user's reward or send encouraging remarks. If the user does not purchase goal insurance, the predefined penalties may be applied upon expiration of a goal time period if the user has not achieved their goal. | 12-30-2010 |
Murugan Govindan, Farmington, CT US
Patent application number | Description | Published |
---|---|---|
20110213626 | SYSTEM AND METHOD FOR EFFICIENT CLAIM ASSIGNMENT - A system includes a data storage device configured to receive and store policy information associated with an insurance policy, and a first data structure associating each of a plurality of program identifiers with a respective claim handling identifier, a computer processor configured to execute program instructions and retrieve the policy information from the data storage device, and a memory, coupled to the computer processor, configured to store program instructions for execution by the computer processor. | 09-01-2011 |
Prakash N. Govindan, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20110056822 | Water Separation Under Reduced Pressure - Water is separated from a liquid mixture (e.g., sea water) using a humidification chamber and a dehumidification chamber that are each operated at a pressure less than ambient atmospheric pressure (e.g., at least 10% less than ambient atmospheric pressure). A carrier gas is flowed through the humidification chamber; and inside the humidification chamber, the carrier gas directly contacts the liquid mixture to humidify the carrier gas with water evaporated from the liquid mixture to produce a humidified gas flow. The humidified gas flow is directed through the dehumidification chamber, where water is condensed from the humidified gas flow and collected. | 03-10-2011 |
20110079504 | Water Separation Under Varied Pressure - Water is substantially separated from a liquid mixture (e.g., saline water) that includes water using a humidification chamber at a lower pressure and a dehumidification chamber at a higher pressure. A carrier gas is flowed through the humidification chamber; and inside the humidification chamber, the carrier gas directly contacts the liquid mixture to humidify the carrier gas with evaporated water from the liquid mixture to produce a humidified gas flow. The humidified gas flow is then directed through the dehumidification chamber, where water is condensed from the humidified gas flow and collected. The absolute pressure inside the humidification chamber is at least 10% lower than the absolute pressure inside the dehumidification chamber. | 04-07-2011 |
20120205236 | High-Efficiency Thermal-Energy-Driven Water Purification System - Water can be separated from a liquid composition, such as salt water, by directing a flow of a carrier gas through at least one evaporator and directly contacting the carrier gas flow with the liquid composition in the evaporator to humidify the carrier gas with water evaporated from the liquid composition, producing a humidified gas flow. The humidified gas flow is then compressed by injecting a fluid that includes steam and/or an organic compound at an elevated pressure at least five times greater than the pressure in the evaporator and at a temperature at least as high as a saturation temperature of the steam/organic compound at the elevated pressure of the fluid. After being compressed, the humidified gas flow is directed through at least one condenser where water is condensed from the compressed humidified gas flow and collected. The dehumidified gas flow is re-circulated from the condenser back through the evaporator, where the dehumidified gas is reused as the carrier gas. | 08-16-2012 |
20130015051 | Separation of a Vaporizable Component Under Reduced Pressure - The productivity of a combined heat and mass transfer device is improved by directing a flow of a carrier-gas mixture through a fluid flow path in a combined heat and mass transfer device operating at a pressure below atmospheric pressure. Heat and mass are transferred from or to the carrier-gas mixture by a direct or indirect interaction with a liquid composition that includes a vaporizable component (e.g., water) in a liquid state to substantially change the content of the vaporizable component in the carrier-gas mixture via evaporation of the vaporizable component from the liquid composition or via condensation of the vaporizable component from the carrier-gas mixture, producing a flow of carrier-gas mixture having a concentration of the vaporizable component that differs from the concentration of the vaporizable component in the carrier-gas mixture before the heat and mass transfer process. | 01-17-2013 |
Prakash Narayan Govindan, Melrose, MA US
Patent application number | Description | Published |
---|---|---|
20150060286 | WATER TREATMENT SYSTEMS AND ASSOCIATED METHODS - Water treatment systems and associated methods are generally described. Certain of the water treatment systems and methods described herein can be used to pre-treat an aqueous stream that is subsequently transported to a desalination apparatus and/or post-treat an aqueous stream that has been produced by a desalination apparatus. | 03-05-2015 |
20150083577 | DESALINATION SYSTEMS AND ASSOCIATED METHODS - Systems and methods related to the desalination of aqueous solutions containing one or more dissolved salts are generally described. | 03-26-2015 |
20150129410 | SYSTEMS INCLUDING A CONDENSING APPARATUS SUCH AS A BUBBLE COLUMN CONDENSER - Condensing apparatuses and their use in various heat and mass exchange systems are generally described. The condensing apparatuses, such as bubble column condensers, may employ a heat exchanger positioned external to the condensing vessel to remove heat from a bubble column condenser outlet stream to produce a heat exchanger outlet stream. In certain cases, the condensing apparatus may also include a cooling device positioned external to the vessel configured and positioned to remove heat from the heat exchanger outlet stream to produce a cooling device outlet stream. The condensing apparatus may be configured to include various internal features, such as a vapor distribution region and/or a plurality of liquid flow control weirs and/or chambers within the apparatus having an aspect ratio of at least 1.5. A condensing apparatus may be coupled with a humidifier to form part of a desalination system, in certain cases. | 05-14-2015 |
20150130093 | SYSTEMS INCLUDING A CONDENSING APPARATUS SUCH AS A BUBBLE COLUMN CONDENSER - Condensing apparatuses and their use in various heat and mass exchange systems are generally described. The condensing apparatuses, such as bubble column condensers, may employ a heat exchanger positioned external to the condensing vessel to remove heat from a bubble column condenser outlet stream to produce a heat exchanger outlet stream. In certain cases, the condensing apparatus may also include a cooling device positioned external to the vessel configured and positioned to remove heat from the heat exchanger outlet stream to produce a cooling device outlet stream. The condensing apparatus may be configured to include various internal features, such as a vapor distribution region and/or a plurality of liquid flow control weirs and/or chambers within the apparatus having an aspect ratio of at least 1.5. A condensing apparatus may be coupled with a humidifier to form part of a desalination system, in certain cases. | 05-14-2015 |
20150190730 | SYSTEMS INCLUDING A CONDENSING APPARATUS SUCH AS A BUBBLE COLUMN CONDENSER - Condensing apparatuses and their use in various heat and mass exchange systems are generally described. The condensing apparatuses, such as bubble column condensers, may employ a heat exchanger positioned external to the condensing vessel to remove heat from a bubble column condenser outlet stream to produce a heat exchanger outlet stream. In certain cases, the condensing apparatus may also include a cooling device positioned external to the vessel configured and positioned to remove heat from the heat exchanger outlet stream to produce a cooling device outlet stream. The condensing apparatus may be configured to include various internal features, such as a vapor distribution region and/or a plurality of liquid flow control weirs and/or chambers within the apparatus having an aspect ratio of at least 1.5. A condensing apparatus may be coupled with a humidifier to form part of a desalination system, in certain cases. | 07-09-2015 |
20150190731 | SYSTEMS INCLUDING A CONDENSING APPARATUS SUCH AS A BUBBLE COLUMN CONDENSER - Condensing apparatuses and their use in various heat and mass exchange systems are generally described. The condensing apparatuses, such as bubble column condensers, may employ a heat exchanger positioned external to the condensing vessel to remove heat from a bubble column condenser outlet stream to produce a heat exchanger outlet stream. In certain cases, the condensing apparatus may also include a cooling device positioned external to the vessel configured and positioned to remove heat from the heat exchanger outlet stream to produce a cooling device outlet stream. The condensing apparatus may be configured to include various internal features, such as a vapor distribution region and/or a plurality of liquid flow control weirs and/or chambers within the apparatus having an aspect ratio of at least 1.5. A condensing apparatus may be coupled with a humidifier to form part of a desalination system, in certain cases. | 07-09-2015 |
20150260418 | Humidification-Dehumidification System with a Bubble-Column Vapor Mixture Condenser and Intermediate Gas Extraction - A humidification-dehumidification system comprises a source of liquid; a humidifier including carrier-gas and liquid inlets and outlets and a chamber in which the liquid can contact a carrier gas containing a condensable fluid in vapor phase that is introduced from the carrier-gas inlet in a counterflow arrangement and in which a portion of the liquid can vaporize into the carrier gas; a bubble-column vapor mixture condenser including at least first and second stages, each stage including a carrier-gas inlet and outlet and a chamber configured to contain a liquid bath in fluid communication with the carrier-gas inlet and the carrier-gas outlet; a conduit passing from the source of the liquid through the chamber of each stage of the bubble-column condenser; and an intermediate exchange conduit coupled with (a) the bubble-column vapor mixture condenser and (b) the humidifier chamber at intermediate stages of each for transfer of the carrier gas therebetween. | 09-17-2015 |
20150290557 | Multi-Stage Bubble-Column Vapor Mixture Condenser - A multi-stage bubble-column vapor mixture condenser comprises at least a first stage and a second stage. Each stage includes a carrier-gas inlet and a carrier-gas outlet, as well as a condenser chamber containing a condensing bath in fluid communication with the carrier-gas inlet and the carrier-gas outlet. The carrier-gas inlet is positioned to bubble carrier gas from the carrier-gas inlet up through the condensing bath, overcoming a hydrostatic head of the condensing bath. The carrier-gas outlet is positioned with an opening for carrier-gas extraction above the condensing bath, wherein the first-stage carrier-gas outlet is in fluid communication with the carrier-gas inlet of the second stage to facilitate flow of the carrier gas through the condensing bath in the condenser chamber of the first stage and then through the condensing bath in the condenser chamber of the second stage. | 10-15-2015 |
20150321118 | Multi-Stage Bubble Column Humidification and Dehumidification - A feed liquid flows into a second-stage humidifier chamber to form a second-stage humidifier bath. A first remnant of the feed liquid from the second-stage humidifier chamber then flows into a first-stage humidifier chamber to form a first-stage humidifier bath having a temperature lower than that of the second-stage bath. A second remnant of the feed liquid is then removed from the first-stage humidifier. Meanwhile, a carrier gas is injected into and bubbled through the first-stage humidifier bath, collecting a vaporizable component in vapor form from the first remnant of the feed liquid to partially humidify the carrier gas. The partially humidified carrier gas is then bubbled through the second-stage humidifier bath, where the carrier gas collects more of the vaporizable component in vapor form from the feed liquid to further humidify the carrier gas before the humidified carrier gas is removed from the second-stage humidifier chamber. | 11-12-2015 |
20150329377 | SYSTEMS INCLUDING A CONDENSING APPARATUS SUCH AS A BUBBLE COLUMN CONDENSER - Condensing apparatuses and their use in various heat and mass exchange systems are generally described. The condensing apparatuses, such as bubble column condensers, may employ a heat exchanger positioned external to the condensing vessel to remove heat from a bubble column condenser outlet stream to produce a heat exchanger outlet stream. In certain cases, the condensing apparatus may also include a cooling device positioned external to the vessel configured and positioned to remove heat from the heat exchanger outlet stream to produce a cooling device outlet stream. The condensing apparatus may be configured to include various internal features, such as a vapor distribution region and/or a plurality of liquid flow control weirs and/or chambers within the apparatus having an aspect ratio of at least 1.5. A condensing apparatus may be coupled with a humidifier to form part of a desalination system, in certain cases. | 11-19-2015 |
Prakash Narayan Govindan, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20130074694 | Bubble-Column Vapor Mixture Condenser - In a bubble-column vapor mixture condenser, a fluid source supplies a carrier-gas stream including a condensable fluid in vapor phase. The condensable fluid in liquid form is contained as a bath in a chamber in each stage of the condenser, and the carrier gas is bubbled through the bath to condense the fluid into the bath. The bubble-column vapor mixture condenser can be used, e.g., in a humidification-dehumidification system for purifying a liquid, such as water. | 03-28-2013 |
20130075940 | Bubble-Column Vapor Mixture Condenser - In a bubble-column vapor mixture condenser, a fluid source supplies a carrier-gas stream including a condensable fluid in vapor phase. The condensable fluid in liquid form is contained as a bath in a chamber in each stage of the condenser, and the carrier gas is bubbled through the bath to condense the fluid into the bath. Energy from condensation is recovered to a liquid composition in a conduit that passes through the liquid in the stages of the condenser. The bubble-column vapor mixture condenser can be used, e.g., in a humidification-dehumidification system for purifying a liquid, such as water. | 03-28-2013 |
20130341810 | Bubble-Column Vapor Mixture Condenser - In a bubble-column vapor mixture condenser, a fluid source supplies a carrier-gas stream including a condensable fluid in vapor phase. The condensable fluid in liquid form is contained as a bath in a chamber in each stage of the condenser, and the carrier gas is bubbled through the bath to condense the condensable fluid into the bath. Energy from condensation is recovered to a coolant in a conduit that passes through the liquid in the stages of the condenser. The bubble-column vapor mixture condenser can be used, e.g., in a humidification-dehumidification system for purifying a liquid, such as water. | 12-26-2013 |
20140014212 | Thermodynamic Balancing of Combined Heat and Mass Exchange Devices - A carrier-gas mixture is directed through a fluid flow path in a combined heat and mass transfer device, which can be operated at sub-atmospheric pressure. Heat and mass are transferred from or to the carrier-gas mixture via interaction with a liquid composition that includes a vaporizable component in a liquid state to substantially change the content of the vaporizable component in the carrier-gas mixture via evaporation or condensation. The mass flow rate of the carrier-gas mixture is varied by extracting or injecting the carrier-gas mixture from at least one intermediate location in the fluid flow path, and/or the mass flow rate of the liquid composition is varied by extracting or injecting the liquid composition from at least one intermediate location in the fluid flow path; and the flow of the carrier-gas mixture or the liquid composition is regulated to reduce the average local enthalpy pinch in the device. | 01-16-2014 |
20140263055 | Ion Sequestration for Scale Prevention in High-Recovery Desalination Systems - Cations that can precipitate from an aqueous composition to produce scaling are sequestered by adding a multi-dentate ligand to the aqueous composition. The multi-dentate ligand bonds with the cation to form a non-scaling ionic complex; and the aqueous solution with the ionic complex is used in a process that produces substantially pure water from the aqueous composition, where the cation, absent formation of the ionic complex, is subject to scaling. The pH of the aqueous composition (or a brine including components of the aqueous composition) is then reduced to release the cation from the multi-dentate ligand; and the multi-dentate ligand, after the cation is released, is then reused in a predominantly closed loop. | 09-18-2014 |
20140367871 | Multi-Stage Bubble Column Humidifier - A feed liquid flows into a second-stage humidifier chamber to form a second-stage humidifier bath. A first remnant of the feed liquid from the second-stage humidifier chamber then flows into a first-stage humidifier chamber to form a first-stage humidifier bath having a temperature lower than that of the second-stage bath. A second remnant of the feed liquid is then removed from the first-stage humidifier. Meanwhile, a carrier gas is injected into and bubbled through the first-stage humidifier bath, collecting a vaporizable component in vapor form from the first remnant of the feed liquid to partially humidify the carrier gas. The partially humidified carrier gas is then bubbled through the second-stage humidifier bath, where the carrier gas collects more of the vaporizable component in vapor form from the feed liquid to further humidify the carrier gas before the humidified carrier gas is removed from the second-stage humidifier chamber. | 12-18-2014 |
Ramaswamy Govindan, St. Louis, MO US
Patent application number | Description | Published |
---|---|---|
20100267574 | PREDICTING LUNG CANCER SURVIVAL USING GENE EXPRESSION - The present invention provides a plurality of biomarkers for predicting survival of a subject with a lung cancer. More specifically, the present invention relates to methods of predicting survival of a subject with a lung cancer, a kit for predicting survival of a subject with a lung cancer, and an array for predicting survival of a subject with lung cancer. | 10-21-2010 |
Ramesh Govindan, Los Angeles, CA US
Patent application number | Description | Published |
---|---|---|
20120106337 | DEVICE AND METHOD FOR ONLINE COMPUTATION OF THE FEASIBLE RATES REGION OF A RAMDOM ACCESS NETWORK - A method is intended for computing online a feasible rates region in a network using a random access MAC protocol and comprising nodes having links there between. This method comprises the steps of i) determining, for each link, a primary extreme point corresponding to a maximum output rate when this link transmits alone at a maximum input rate, and ii) determining secondary extreme points by combining these primary extreme points with a chosen interference model, these primary and secondary extreme points defining a boundary of a feasible rates region. | 05-03-2012 |
20120113836 | DEVICE AND METHOD FOR COMPUTATION OF CHANNEL LOSS RATE AND COLLISION LOSS RATE OF COMMUNICATION LINK(S) IN A RANDOM ACCESS NETWORK - A method is intended for computing online channel loss rate and collision loss rate of at least one communication link established between nodes of a network using a random access MAC protocol. This method comprises the steps of i) dividing time in probing windows and transmitting a chosen number S of probe packets during each probing window from a transmitter node to a receiver node linked therebetween, ii) measuring a packet loss rate from probe packets lost on this communication link during a probing window, iii) scanning each probing window with smaller sliding windows, each having a size Wk smaller than S, to identify the sliding window during which only channel losses occur, and then for computing a channel loss rate on this communication link from this identified sliding window, and iv) computing a collision loss rate on this communication link by subtracting the computed channel loss rate from the measured packet loss rate. | 05-10-2012 |
20140369227 | DEVICE AND METHOD FOR COMPUTATION OF CHANNEL LOSS RATE AND COLLISION LOSS RATE OF COMMUNICATION LINK(S) IN A RANDOM ACCESS NETWORK - A method is intended for computing online channel loss rate and collision loss rate of at least one communication link established between nodes (N | 12-18-2014 |
Serengulam V. Govindan, Summit, NJ US
Patent application number | Description | Published |
---|---|---|
20090291093 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate. | 11-26-2009 |
20100015046 | Camptothecin-Binding Moiety Conjugates - The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates. | 01-21-2010 |
20100104589 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 04-29-2010 |
20100221177 | RS7 Antibodies - This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy. | 09-02-2010 |
20100233779 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites - The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided. | 09-16-2010 |
20110070156 | Combining Radioimmunotherapy and Antibody-Drug Conjugates for Improved Cancer Therapy - Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice. | 03-24-2011 |
20110293513 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 12-01-2011 |
20110305631 | Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases - Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other. Administration of the anti-CD22 antibody and therapeutic agent induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. | 12-15-2011 |
20120040431 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites - The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided. | 02-16-2012 |
20120082617 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 04-05-2012 |
20120141372 | RS7 Antibodies - This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy. | 06-07-2012 |
20120328564 | Camptothecin-Binding Moiety Conjugates - The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates. | 12-27-2012 |
20120328634 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate. | 12-27-2012 |
20130072659 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites - The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided. | 03-21-2013 |
20130090458 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 04-11-2013 |
20130177526 | Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases - Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD 19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other. Administration of the anti-CD22 antibody and therapeutic agent induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. | 07-11-2013 |
20130209356 | Combining Radioimmunotherapy and Antibody-Drug Conjugates for Improved Cancer Therapy - Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice. | 08-15-2013 |
20130216561 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The invention relates to therapeutic conjugates with improved ability to target various cancer cells containing a targeting moiety and a therapeutic moiety. The targeting and therapeutic moieties are linked via an acid cleavable linkage that increases therapeutic efficacy of the immunoconjugate. | 08-22-2013 |
20140004078 | Immunoconjugates with an Intracellularly-Cleavable Linkage | 01-02-2014 |
20140044640 | Combining Radioimmunotherapy and Antibody-Drug Conjugates for Improved Cancer Therapy - Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice. | 02-13-2014 |
20140058067 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 02-27-2014 |
20140099258 | Camptothecin-Binding Moiety Conjugates - The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates. | 04-10-2014 |
20140120035 | RS7 Antibodies - This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy. | 05-01-2014 |
20140170063 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 ROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 06-19-2014 |
20140219914 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 08-07-2014 |
20140219956 | PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER - Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease. | 08-07-2014 |
20140286860 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 09-25-2014 |
20140286861 | RS7 Antibodies - This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy. | 09-25-2014 |
20140328752 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 11-06-2014 |
20140369927 | Camptothecin Conjugates of Anti-CD22 Antibodies for Treatment of B Cell Diseases - Disclosed herein are compositions and methods of use comprising combinations of anti-CD22 antibodies with a therapeutic agent. The therapeutic agent may be attached to the anti-CD22 antibody or may be separately administered, either before, simultaneously with or after the anti-CD22 antibody. In preferred embodiments, the therapeutic agent is an antibody or fragment thereof that binds to an antigen different from CD22, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80 and HLA-DR. However, the therapeutic agent may an immunomodulator, a cytokine, a toxin or other therapeutic agent known in the art. More preferably, the anti-CD22 antibody is part of a DNL complex, such as a hexavalent DNL complex. Most preferably, combination therapy with the anti-CD22 antibody or fragment and the therapeutic agent is more effective than the antibody alone, the therapeutic agent alone, or the combination of anti-CD22 antibody and therapeutic agent that are not conjugated to each other. Administration of the anti-CD22 antibody and therapeutic agent induces apoptosis and cell death of target cells in diseases such as B-cell lymphomas or leukemias, autoimmune disease or immune dysfunction disease. | 12-18-2014 |
20140377287 | ANTI-TROP-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF - Described herein are compositions and methods of use of antibody-drug conjugates (ADCs) comprising an anti-Trop-2 antibody or antigen-binding fragment thereof, conjugated to one or more cytotoxic drugs. Preferably, the antibody is an RS7, 162-46.2 or MAB650 antibody. More preferably, the antibody is humanized. Preferably the drug is SN-38, pro-2-pyrrolinodoxorubicin, paclitaxel, calichemicin, DM1, DM3, DM4, MMAE, MMAD or MMAF. The compositions and methods are of use to treat Trop-2 expressing cancers, such as breast, ovarian, cervical, endometrial, lung, prostate, colon, stomach, esophageal, bladder, renal, pancreatic, thyroid, epithelial or head-and-neck cancer. Preferably, the cancer is one that is resistant to one or more standard cancer therapies. More preferably, the anti-Trop-2 antibody binds to Trop-2 expressed on normal cells, but administration of the anti-Trop-2 ADC to human cancer patients at a therapeutically effective dosage produces only limited toxicity. | 12-25-2014 |
20150018516 | PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER - Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease. | 01-15-2015 |
20150038686 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites - The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided. | 02-05-2015 |
20150174269 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 06-25-2015 |
20150174270 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 06-25-2015 |
20150182633 | Immunoconjugates with an Intracellularly-Cleavable Linkage - The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates. | 07-02-2015 |
20150196653 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 07-16-2015 |
20150196654 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 07-16-2015 |
20150196661 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 07-16-2015 |
20150196662 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 07-16-2015 |
20150196664 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 07-16-2015 |
20150196665 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 07-16-2015 |
20150196666 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 07-16-2015 |
20150202319 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 07-23-2015 |
20150202320 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 07-23-2015 |
20150216997 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 08-06-2015 |
20150283264 | PRO-DRUG FORM (P2PDOX) OF THE HIGHLY POTENT 2-PYRROLINODOXORUBICIN CONJUGATED TO ANTIBODIES FOR TARGETED THERAPY OF CANCER - Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the ADC or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-PDox) is released intracellularly. The P2PDox-peptide or ADC conjugates are of use to treat a wide variety of diseases, such as cancer, autoimmune disease or infectious disease. | 10-08-2015 |
20150306243 | ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER - The present invention concerns improved methods and compositions for preparing SN-38 conjugates of proteins or peptides, preferably immunoconjugates of antibodies or antigen-binding antibody fragments. More preferably, the SN-38 is attached to the antibody or antibody fragment using a CL2A linker, with 1-12, more preferably 6 or less, most preferably 1-5 SN-38 moieties per antibody or antibody fragment. Most preferably, the immunoconjugate is prepared in large scale batches, with various modifications to the reaction scheme to optimize yield and recovery in large scale. Other embodiments concern optimized dosages and/or schedules of administration of immunoconjugate to maximize efficacy for disease treatment and minimize side effects of administration. | 10-29-2015 |
Sibi Govindan, Austin, TX US
Patent application number | Description | Published |
---|---|---|
20150363116 | MEMORY CONTROLLER POWER MANAGEMENT BASED ON LATENCY - A processor monitors, directly or indirectly, the amount of time it takes for the memory controller to respond to one or more memory access requests. When this memory access latency indicates that a memory latency tolerance of a program thread has been exceeded, the processor can apportion additional power to the memory controller, thereby increasing the speed with which the memory controller can process memory access requests. | 12-17-2015 |
Sriram Govindan, Redmond, WA US
Patent application number | Description | Published |
---|---|---|
20130345887 | INFRASTRUCTURE BASED COMPUTER CLUSTER MANAGEMENT - Various techniques of managing a computer cluster are disclosed herein. In one embodiment, a method for managing a computer cluster includes receiving a request for a computing operation, obtaining information of utility for the computer cluster, and determining an execution profile of the computing operation identified by the received request based at least in part on the obtained information. The information includes at least one of a configuration or condition of power, heating, cooling, ventilation that supports the computer cluster. The method also includes executing the computing operation in the computer cluster in accordance with the determined execution profile. | 12-26-2013 |
20140189706 | RELIABILITY-AWARE APPLICATION SCHEDULING - Reliability-aware scheduling of processing jobs on one or more processing entities is based on reliability scores assigned to processing entities and minimum acceptable reliability scores of processing jobs. The reliability scores of processing entities are based on independently derived statistical reliability models as applied to reliability data already available from modern computing hardware. Reliability scores of processing entities are continually updated based upon real-time reliability data, as well as prior reliability scores, which are weighted in accordance with the statistical reliability models being utilized. Individual processing jobs specify reliability requirements from which the minimum acceptable reliability score is determined. Such jobs are scheduled on processing entities whose reliability score is greater than or equal to the minimum acceptable reliability score for such jobs. Already scheduled jobs can be rescheduled on other processing entities if reliability scores change. Additionally, a hierarchical scheduling approach can be utilized. | 07-03-2014 |
20140380334 | HARDWARE MANAGEMENT COMMUNICATION PROTOCOL - A simplified hardware management communication protocol comprises defined request packets, which are utilized to transmit requests to lower layers of management functionality or to managed resources, and it also comprises defined response packets, which are utilized to transmit responses back to the source of the request. A request packet comprises an identification of a type of device, an identifier of that device, an address of the sending entity, a session identifier, a sequence number, a function identifier, and a payload that comprises encapsulated communications or data directed to the request target. A response packet can comprise an identification of the sender of the request, a session identifier, a sequence number, a completion code identifying whether and how the request was completed, and a payload. Managed asset type specific drivers translate into communications utilizing communicational protocols that are specific to the managed assets. | 12-25-2014 |
20150134723 | GEO-DISTRIBUTED DISASTER RECOVERY FOR INTERACTIVE CLOUD APPLICATIONS - Disaster recovery is provided for an application that is being hosted on a current data center, thus ensuring the availability of the application. An option for replicating session state data for the application is selected. This selection is made from a set of different session state data replication options each of which has different performance and resource cost trade-offs. The selected option determines how the session state data for the application is to be replicated. The selected option is implemented, where the implementation results in the session state data for the application being replicated outside of the current data center, thus ensuring that this data remains available in the event that the current data center goes offline. | 05-14-2015 |
20150192936 | Datacenter And Cooling Control Fault-Tolerance Using Compute Resources - Management of infrastructure devices is performed by computing devices that are associated with the processing being provided by the data center, such as chassis managers. A master is first selected through polling or consensus algorithms, and then subsequently the master is endowed with the authority to manage infrastructure devices and generate the control output to such infrastructure devices. Alternatively, no master need be elected and, instead, output to such infrastructure devices is generated by a computing device selected utilizing polling or consensus algorithms, and in accordance with a management decision made through polling or consensus algorithms. The interplay between the cooling apparatuses of individual server computing devices and the cooling apparatuses of the data center as a whole is also managed to increase the portion of the cooling of server computing devices provided by data center air movers. Control of data center air movers can be determined empirically or predictively. | 07-09-2015 |
20150227181 | BACKUP POWER MANAGEMENT FOR COMPUTING SYSTEMS - Various techniques for managing power backup for computing devices are disclosed herein. In one embodiment, a method includes receiving data representing a backup capacity of one or more backup power units and data representing a backup power profile of one or more processing units sharing the one or more backup power units. A portion of the backup capacity may then be assigned to each of the one or more processing units based at least in part on both the received data representing the backup capacity of the one or more backup power units and the received data representing the profile of the one or more processing units. | 08-13-2015 |
Sriram Govindan, State College, PA US
Patent application number | Description | Published |
---|---|---|
20100011227 | SYSTEM AND METHOD FOR MEASUREMENT-BASED POWER AND ENERGY ACCOUNTING FOR VIRTUAL MACHINES - A method for measurement-based power and energy accounting for virtual machines distributed among at least one hosting device is disclosed. The method comprising determining an energy for the hosting device during a first time interval and a second time interval, partitioning a difference in the determined energy among virtual machines within a plurality of regions of the hosting device, determining a level of activity of each of the resources in each virtual machine within a corresponding one of the regions, determining an energy of each resource in each corresponding virtual machine wherein energy associated with resources shared among an plurality of virtual machines are allocated to a corresponding one of the virtual machines based on a number of requests made to the shared resource by the corresponding virtual machine, determining a total energy for each of the virtual machines in corresponding regions based on a level of activity of the virtual machine and the energy associated with the corresponding shared resources, and determining a power for each of the virtual machines by dividing the determined total energy by a length of the time interval. | 01-14-2010 |
20120023492 | WORKLOAD INTERFERENCE ESTIMATION AND PERFORMANCE OPTIMIZATION - Architecture that facilitates the estimation of interference among workloads (e.g., virtual machines) due to sharing of a shared resource (e.g., a shared cache of a computer processor), and optimization of a desired performance objective such as power or energy use in the presence of the interference. Estimation is to the extent of interference by characterizing the nature of shared resource usage and its effect on performance. Performance optimization is accomplished using metrics based on the above estimation, or alternatively, an explicit measurement of the interference effects. Methods are employed to estimate interference on the workload's performance with changes in availability of the shared resource or with combinations of other workloads sharing the same resource and allocating workloads to one or more physical computers or resources to workloads such that a desired performance objective is optimized. The methods can include allocating workloads on demand. | 01-26-2012 |
20140201741 | WORKLOAD INTERFERENCE ESTIMATION AND PERFORMANCE OPTIMIZATION - Architecture that facilitates the estimation of interference among workloads (e.g., virtual machines) due to sharing of a shared resource (e.g., a shared cache of a computer processor), and optimization of a desired performance objective such as power or energy use in the presence of the interference. Estimation is to the extent of interference by characterizing the nature of shared resource usage and its effect on performance. Performance optimization is accomplished using metrics based on the above estimation, or alternatively, an explicit measurement of the interference effects. Methods are employed to estimate interference on the workload's performance with changes in availability of the shared resource or with combinations of other workloads sharing the same resource and allocating workloads to one or more physical computers or resources to workloads such that a desired performance objective is optimized. The methods can include allocating workloads on demand. | 07-17-2014 |
Vidya Govindan, Vallejo, CA US
Patent application number | Description | Published |
---|---|---|
20130066936 | Proximal Adaptive Collapsed Cloud Systems - A collapsed cloud proximal to the user of a client device determines, stores, and provides access to content needed by the user or group of users. Content needed by the user is pushed into one or more access points that a client device is accessing or is expected to access. The client device accesses the content via local access to the access point(s) that it connects to, access relevant content from the local storage of the access point that it connects to as it moves. | 03-14-2013 |
Vidya Govindan, San Ramon, CA US
Patent application number | Description | Published |
---|---|---|
20150285398 | METHOD FOR TRANSMITTING DATA FOR DEVICE DIAGNOSTICS AND IMPLEMENTATIONS THEREOF - A method that simplifies the exchange of data to facilitate delivery of data that relates to operation of a valve assembly to a Web-based user interface over a network. In one embodiment, the method configures an apparatus to receive data about the valve assembly in a first format and to generate an output in a second format, e.g., JavaScript Object Notation (JSON) format. The method may also configure the device with an architecture with multiple layers, wherein the architecture can exchange data in the JSON format between a first layer and a second layer. This architecture is configured to be lightweight as compared to the SOAP/HTTP architecture found in conventional techniques, typically deploying a Representational State Transfer (REST) structure that permits use of JavaScript Object Notation (JSON) format to communicate among the architecture layers and with the web-based user interface. | 10-08-2015 |
20150286614 | SYSTEM AND METHOD TO DISPLAY DATA DEFINING OPERATION OF A VALVE ASSEMBLY ON A TREND GRAPH ON A USER INTERFACE - A system and a method to display diagnostic and operating data on a trend graph via a web browser so that the data appears to trend in real-time. In one embodiment, the system includes a server with an architecture having multiple layers. The layers include a pair of first in, first out (FIFO) data queues including a first data queue and a second data queue. The embodiments utilize a timing structure with a plurality of timers including a first timer to regulate calls from the first data queue to a data source (e.g., a valve assembly or controller on a distributed control system), a second timer to regulate calls from the second data queue to the first data queue, and a third timer to regulate calls from the web browser to the second data queue for data to display on trend graph. | 10-08-2015 |